why choose us

First received: September 19, 2022

Clinical Trial: Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent Chronic Myelomonocytic Leukemia

Study Type: INTERVENTIONAL


Official Title: Phase 1 Study to Determine the Safety and Efficacy of Onvansertib, A Novel, Oral, PLK1 Inhibitor in Patients With Proliferative Chronic Myelomonocytic Leukemia (CMML) Relapsed/Refractory or Intol

Brief Summary: This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that has come back (recurrent) or that does not respond to treatment (refractory).Onvansertib is a drug that binds to and inhibits an enzyme called PLK1, preventing cancer cell proliferation and causing cell death.

Read more